ME1 Stock Overview
Melodiol Global Health Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and other health in Europe, Canada, the Asia Pacific, the United States, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Melodiol Global Health Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.004 |
52 Week High | AU$0.44 |
52 Week Low | AU$0.004 |
Beta | 2.55 |
1 Month Change | -11.11% |
3 Month Change | -80.00% |
1 Year Change | -98.00% |
3 Year Change | -99.89% |
5 Year Change | -99.95% |
Change since IPO | -99.92% |
Recent News & Updates
Shareholder Returns
ME1 | AU Pharmaceuticals | AU Market | |
---|---|---|---|
7D | -20.0% | -3.0% | -2.2% |
1Y | -98.0% | 37.1% | 4.5% |
Return vs Industry: ME1 underperformed the Australian Pharmaceuticals industry which returned 32.4% over the past year.
Return vs Market: ME1 underperformed the Australian Market which returned 4% over the past year.
Price Volatility
ME1 volatility | |
---|---|
ME1 Average Weekly Movement | 43.9% |
Pharmaceuticals Industry Average Movement | 11.1% |
Market Average Movement | 9.0% |
10% most volatile stocks in AU Market | 17.6% |
10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: ME1's share price has been volatile over the past 3 months.
Volatility Over Time: ME1's weekly volatility has decreased from 51% to 44% over the past year, but is still higher than 75% of Australian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | n/a | Will Lay | melodiolglobalhealth.com |
Melodiol Global Health Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and other health in Europe, Canada, the Asia Pacific, the United States, and internationally. The company develops and commercializes therapeutic products; develops and sells beauty and personal care products under the Green Goo, Southern Butter, and Goodgoo brands; and cultivates, processes, and sells cannabis products. Its products include cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and minerals in a lozenge delivery system; the ImpACTIVE Pro Releaf Stick to provide relief to muscle aches, particularly in professional sport, and acts as an alternative to pharmacological solutions sold through online channels; Ritual Green, a dried flower; Ritual Sticks for pre-rolled joints; and Ritual Gold, a handheld vapouriser.
Melodiol Global Health Limited Fundamentals Summary
ME1 fundamental statistics | |
---|---|
Market cap | AU$2.15m |
Earnings (TTM) | -AU$35.52m |
Revenue (TTM) | AU$18.92m |
0.1x
P/S Ratio-0.1x
P/E RatioIs ME1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ME1 income statement (TTM) | |
---|---|
Revenue | AU$18.92m |
Cost of Revenue | AU$18.10m |
Gross Profit | AU$817.00k |
Other Expenses | AU$36.34m |
Earnings | -AU$35.52m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.066 |
Gross Margin | 4.32% |
Net Profit Margin | -187.73% |
Debt/Equity Ratio | -232.0% |
How did ME1 perform over the long term?
See historical performance and comparison